Unicycive Therapeutics, Inc. (UNCY) Earnings History
Annual and quarterly earnings data from 2018 to 2024
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | 100.0% | -3077.6% | -4525.0% |
| 2022 | 100.0% | -1898.2% | -1898.8% |
| 2021 | - | - | - |
| 2020 | - | - | - |
Download Data
Export UNCY earnings history in CSV or JSON format
Free sign-in required to download data
Unicycive Therapeutics, Inc. (UNCY) Earnings Overview
As of March 1, 2026, Unicycive Therapeutics, Inc. (UNCY) reported trailing twelve-month net income of -$33M, reflecting -3.4% year-over-year growth. The company earned $-1.85 per diluted share over the past four quarters.
Looking at the long-term picture, UNCY's historical earnings data spans multiple years. The company achieved its highest annual net income of -$1M in fiscal 2018.
Unicycive Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to industry peers including UTHR ($1.33B net income, 0.4% margin), ZLAB (-$176M net income, -0.4% margin), AMRN (-$86M net income, -0.4% margin), UNCY has comparable earnings metrics. Compare UNCY vs UTHR →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$37M | -20.2% | -$32M | $-5.60 | - | - |
| 2023 | -$31M | -69.1% | -$21M | $-1.28 | -4525.0% | -3077.6% |
| 2022 | -$18M | -80.3% | -$18M | $-1.20 | -1898.8% | -1898.2% |
| 2021 | -$10M | -299.4% | -$9M | $-8.60 | - | - |
| 2020 | -$3M | -8.9% | -$2M | $-0.16 | - | - |
| 2019 | -$2M | -105.7% | -$2M | $-0.27 | - | - |
| 2018 | -$1M | - | $-952,000 | $-0.14 | - | - |
See UNCY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs UNCY Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare UNCY vs AGIO
See how UNCY stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is UNCY growing earnings?
UNCY EPS of $-1.85 reflects slowing growth at -3.4%, below the 5-year CAGR of N/A. TTM net income is $-33M. Expansion rate has moderated.
What are UNCY's profit margins?
Unicycive Therapeutics, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are UNCY's earnings?
UNCY earnings data spans 2018-2024. The current earnings trend is -3.4% YoY. Historical data enables comparison across business cycles.